ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first European ...

Geographic atrophy management could benefit greatly from the combination of novel therapies and AI-driven imaging technology.

The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and ...

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal ...

Experts believe the retina may predict Alzheimer's risk because it is part of the central nervous system and connected ...

Apellis (APLS) stock gains as Roth launches its coverage with a Buy rating and a $31 target, citing its lead asset Syfovre.

Schulman, Ph.D. We have known for some time that changes in the eye may help detect Alzheimer’s disease — a type of dementia affecting about 32 million people globally. Previous research has linked ...

Zhou lost his sight in childhood, initially thought to be caused by congenital retinal atrophy but later diagnosed as retinitis pigmentosa, a group of inherited rare retinal disorders that lead to ...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...